Our meta-analysis showed that in a group of ten studies that met the inclusion criteria [29,31,32,33,34,35,36,37,38,39], KRAS mutations conferred an increased risk of not responding to neoadjuvant treatment (i.e., no-pCR), which is consistent with pre-clinical observations in rectal cancer and the well-established detrimental impact of KRAS mutations on the behavior of other tumors. Here, KRAS is linked to rectal cancer.